title: Anti-polyribosylribitol phosphate antibody in pediatric patients with Haemophilus influenzae type b invasive disease.
abstract: Haemophilus influenzae type b conjugate vaccine was recently introduced to Japan for voluntary immunizations. H. influenzae type b remains a leading cause of pediatric invasive diseases in Japan. The purposes of this study were to verify the suitability of the H. influenzae type b conjugate vaccine for immunizing children with a history of invasive H. influenzae type b disease and to determine whether H. influenzae type b conjugate vaccine is immunogenic in these children. The subjects comprised 64 children with a history of invasive H. influenzae type b disease. Serum samples from 64 patients with H. influenzae type b systemic infection in the acute and convalescent phases were analyzed. Serum anti-polyribosylribitol phosphate antibody responses of patients < 2 years old were poorer than those observed in patients ≥ 2 years old. Nineteen of the 64 patients received a single dose of H. influenzae serotype b conjugate vaccine, and then follow-up serum was taken and analyzed. Eighteen of 19 patients had ≥ 1 μg/mL of anti-polyribosylribitol phosphate antibody titer after the first dose of H. influenzae type b conjugate vaccine. H. influenzae type b conjugate vaccine is immunogenic in children with invasive H. influenzae type b disease. Children < 4 years old, and particularly < 2 years old, with invasive H. influenzae type b disease should receive subsequent immunization with a H. influenzae type b conjugate vaccine.
authors.affiliation: Department of Pediatrics, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8677, Japan. ishiwada@faculty.chiba-u.jp
authors.forename: Naruhiko
authors.initials: N
authors.lastname: Ishiwada
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Honda
authors.forename: Junko
authors.initials: J
authors.lastname: Tanaka
authors.forename: Haruka
authors.initials: H
authors.lastname: Hishiki
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kohno
mesh_terms: D000293:Adolescent; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D016667:Bacterial Capsules / Q000008:administration & dosage* / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan; D011134:Polysaccharides / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology; D055815:Young Adult
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011134:Polysaccharides; D018074:Vaccines, Conjugate; C008984:polyribitol phosphate